<--- Back to Details
First PageDocument Content
Medicine / Finnish heritage disease / Compound heterozygosity / Lysosomal storage disease / Neuronal ceroid lipofuscinosis / Congenital chloride diarrhea / Linkage disequilibrium / Congenital nephrotic syndrome / CLN3 / Health / Rare diseases / Biology
Medicine
Finnish heritage disease
Compound heterozygosity
Lysosomal storage disease
Neuronal ceroid lipofuscinosis
Congenital chloride diarrhea
Linkage disequilibrium
Congenital nephrotic syndrome
CLN3
Health
Rare diseases
Biology

Add to Reading List

Source URL: hmg.oxfordjournals.org

Download Document from Source Website

File Size: 264 B

Share Document on Facebook

Similar Documents

Medicine / Health / Clinical medicine / Rare diseases / Porphyrias / Lysosomal storage diseases / RTT / Erythropoietic protoporphyria / Glycogen storage disease type II / Disease

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

Biology / Cell biology / Anatomy / Cellular processes / Vesicles / NPC1 / Cardiology / Lipoproteins / Cholesterol / Lysosomal storage disease / LAMP1 / Low-density lipoprotein

CrossMark_Color_flat+click

DocID: 1r0lC - View Document

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

Mucopolysaccharidosis / Hunter syndrome / Hurler syndrome / Morquio syndrome / Sanfilippo syndrome / Maroteaux–Lamy syndrome / Genetic disorder / Lysosomal storage disease / Sly syndrome / Health / Syndromes / Rare diseases

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document